Loading stock data…
Neuraxis, Inc. (NRXS)
$5.91-0.05 (-0.84%)
Market ClosedLast close Sep 8
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeurAxis, Inc. in the Healthcare sector is trading at $5.91 with a market capitalization of $88M. Wall Street consensus targets $11.00 (2 analysts), implying a +86.1% move over the next 12 months. The stock is currently 37% below its 52-week high of $9.33, remaining 0.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +86.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.61M↑ | $968,127↑ | $811,414↓ | $894,086↓ | $895,655 |
| Gross Profit | $1.39M↑ | $826,476↑ | $675,927↓ | $747,443↓ | $756,180 |
| Operating Income | -$1.74M↓ | -$1.72M↑ | -$2.10M↓ | -$1.72M↑ | -$2.30M |
| Net Income | -$1.76M↓ | -$1.71M↑ | -$2.12M↓ | -$1.69M↑ | -$2.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimula...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$87.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-126.72%
Volume
Today's trading volume
54,533
Recent News
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
NeurAxis, Inc. Q2 2026 Earnings Call Summary
Moby summary of NeurAxis, Inc.'s Q2 2026 earnings call
Neuraxis Inc (NRXS) (Q2 2026) Earnings Call Highlights: Revenue Surges 116% as Payer Coverage ...
Neuraxis Inc (NRXS) reports record Q2 growth with gross margins expanding to 85.9% while strategically investing in VA channel expansion and large payer negotiations.
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.